

REVIEW

Open Access



# Stress, pseudoallergens, autoimmunity, infection and inflammation in chronic spontaneous urticaria

Ciara Jade Bansal<sup>1</sup> and Amolak Singh Bansal<sup>2\*</sup>

## Abstract

Chronic spontaneous urticaria (CSU) is often associated with organ specific autoimmunity but is rarely caused by food allergy. Colourings and preservatives in pre-packaged foods, so called pseudoallergens, have also been implicated. Factors that promote inflammation or reduce anti-inflammatory mechanisms may however, predispose susceptible individuals to CSU. Chronic underlying infection and mental and emotional stress can sometimes precede the onset of CSU and once established can exacerbate the symptoms. There is early evidence of dysbiosis within the gastrointestinal tract in people with CSU and reduced levels of vitamin D are also evident. The latter may be related to the importance of vitamin D3 in increasing T regulatory function which can control a tendency to autoimmunity. It is quite possible that a state of on-going chronic inflammation with reduced anti-oxidant mechanisms may underlie the not infrequent association between CSU and metabolic syndrome. Effective treatment of CSU should involve the use of anti-histamines, intermittent steroids and anti-IgE therapy. For recalcitrant disease immune modulatory therapy has a place. However, talking therapies that reduce stress and anxiety, vitamin D3 supplementation, correction of intestinal dysbiosis and treatment of any chronic infection should also be considered.

**Keywords:** Chronic urticaria, Pseudoallergens, Stress, Infections, Autoimmunity, Cofactors, Vitamin D3

## Background

Chronic spontaneous urticaria (CSU) is generally defined as recurrent urticaria present continuously or intermittently for 6 or more weeks. Most cases of acute urticaria resolve—less than 8% will continue to CSU [1]. It is frequently a mast cell driven disease with clinical features arising from the action of several factors released by activated and degranulated mast cells. Indeed, mast cell numbers are increased three fold in the involved and uninvolved skin of patients with CSU [2]. It has been estimated to present a lifetime risk of 20% and with an annual prevalence of approximately 0.02 to 0.5% [3, 4]. CSU is more frequent in females with a male to female ratio varying between 1.5:1 to 2:1. Such female preponderance is evident in many of the organ specific and systemic autoimmune diseases [5]. While

autoimmune disease (21%), chronic infection (29%) and immune dysfunction (4%) may become evident over time, CSU remains idiopathic in 45% even after 10 years of follow-up [6].

Aetiologically, and despite the unequivocal benefit of anti-IgE therapy in severe CSU [7], IgE mediated type I food allergy is considered rare [8], although associated atopy is increased, especially in adolescents with CSU [9]. Much recent work has focused on other mechanisms leading to mast cell activation which is critical to CSU [7]. In particular, this includes autoimmunity type IIb with IgG anti-IgE auto-antibodies and positive autologous serum skin tests. Other mechanisms include type I IgE auto-antibodies directed at self-antigens, CD4-positive T cells directed at the high-affinity IgE receptor, immune cell activating IgE, and histamine-releasing factors able to bind to IgE. More recent work suggests a central importance of the Mas related G protein coupled X2 receptor (MRGPRX2) that is found on mast cells. This can be stimulated by the neuropeptides released by stress,

\*Correspondence: Amolak.Bansal@nhs.net

<sup>2</sup> St Helier Hospital, Carshalton, Surrey SM5 1AA, UK

Full list of author information is available at the end of the article



defensins, pseudoallergens and various medications [10, 11]. This is summarised in Fig. 1.


CSU is associated with several disorders which either predispose to the condition or facilitate mast cell degranulation. Additionally, several conditions appear to frequently co-exist with CSU and appear to be linked by a common underlying pro-inflammatory state. These are summarised in Table 1. In many patients with CSU the unpredictability of the urticarial wheals and overwhelming nature of the itching can lead to persistent stress [12]. This is frequently associated with a significant alteration of mood and a markedly reduced quality of life [13, 14]. Each of these factors should be addressed in the investigation and management of patients with CSU. Certainly, efforts to reduce these variables may lessen the severity and duration of the condition with a lowered need to use second and third line therapies.

### Aetiological and associated factors in CSU

#### Pseudoallergens

The importance of low molecular weight preservatives, colourings, salicylates and histamine in CSU has waxed and waned over the years. While salicylate mediated inhibition of cyclooxygenase 1 leading to a disturbance in a healthy prostaglandin/leukotriene ratio [15, 16] may underlie an exacerbation of CSU in some patients, the factors other than polymorphisms in centrosomal protein of 68 kDa [17] that predispose to this are unclear.

Clearly, the small size of these molecules makes it impossible for them to directly bind IgE and there is no evidence that they act as haptens. Nevertheless, there is compelling evidence that a significant proportion of patients with CSU may benefit from a diet low in these 'pseudoallergens' [18–21]. This was associated with reduced leukotriene E4 excretion in the urine compared to pre-diet levels [18]. However, provocation testing with 'known food dyes and preservatives' was positive in only 18% of CSU patients although 73% had originally responded to the pseudoallergen free diet [22]. Interestingly, 71% of these patients reacted to provocation testing with pureed tomato and 41% to a steam extract to tomatoes. In a similar way, Rajan et al. [23] noted only 2 of their 100 patients with CSU reacted to a single blind challenge with 11 of the most frequently used additives. Finally, intestinal permeability was reported to be increased in CSU and this was partly reversed by 24 days on a reduced pseudoallergen diet [24]. Collectively, these results suggest that CSU may in some people be due to a temporary sensitivity to pseudoallergens and natural low molecular weight compounds which enter the body across a leaky gut epithelium. The pseudoallergens may in themselves also contribute to the leaky gut but it is likely that other factors may be responsible for raising mast cell sensitivity to the pseudoallergens. However, once these additional factors have subsided then normal resistance to these compounds may once again prevail.



**Table 1 Conditions associated with affecting the prevalence and severity of CSU**

| Variable                            | Contribution to CSU                 | Outline of purported mechanism   |
|-------------------------------------|-------------------------------------|--|
| Autoimmunity                        | Predisposing factor                 | CSU is more frequent in females, associated with a positive autologous serum skin test and is frequently associated with underlying autoimmunity and altered T cells subsets. Diversely autoreactive IgE and IgG autoimmunity is particularly frequent in CSU. Benefit with anti-IgE therapy suggests direct ability of IgE auto-antibodies in triggering mast cell degranulation  |
| Pseudoallergens                     | Facilitating factor                 | These low molecular weight compounds may bind to mast cell Mas related G protein coupled receptor X2 and lower the threshold for other factors to fully activate the mast cells to release CSU mediators. Salicylates and non-steroidal anti-inflammatory drugs in predisposed individuals increase overall leukotriene activity by COX-1 inhibition. These then lead to mast cell activation and increased CSU activity |
| Stress                              | Facilitating or predisposing factor | Increased inflammation with altered T cell subsets and a reduction in Tregs especially leading to impaired B cell control. Stress released neuropeptides can also activate mast cells via Mas related G protein coupled receptor X2  |
| Parasitic infection                 | Predisposing factor                 | Parasites stimulate humoral autoimmunity especially a polyclonal IgE which may have auto-reactive components   |
| Helicobacter gastritis              | Predisposing factor                 | While the frequency of helicobacter infection may be higher in CSU patients evidence of anti-helicobacter therapy being effective is conflicting   |
| Metabolic syndrome                  | Co-morbid condition                 | Both CSU and metabolic syndrome are associated with increased background inflammation. As such the association between these may be due to the chronic inflammation being common to both   |
| Hypertension                        | Co-morbid condition                 | CSU more likely to be prolonged in patients with hypertension; hazard ratio 0.71   |
| Dysbiosis of gastrointestinal tract | Predisposing factor                 | Reductions in several types of bacteria in the stools of those with CSU but not enterobacteriaceae. Altered bowel microbiota may lead to increased gut epithelial permeability and absorption of immune activating compounds   |
| Vitamin D3                          | Facilitating factor                 | Low levels found in CSU. Vitamin D3 reduces Th1 and Th17 cells and increases T regulatory cell function that can reduce autoimmunity and reduce inflammation   |

### Autoimmunity

The presence of a positive autologous serum (AST) or plasma test (APT) in 40% to 60% of patients with CSU has suggested the presence of auto-antibodies capable of stimulating mast cells [25]. Importantly, a positive AST has been shown to increase the possibility of acute spontaneous urticaria progressing to CSU [26] and a reduced chance of resolution within 2 years [27].

Several types of autoimmune diseases are increased in patients with CSU (Table 2). These include particularly hypo and hyperthyroidism but also diabetes, rheumatoid arthritis and Sjogren's syndrome [28]. IgG anti-thyroid antibodies, in particular, are not infrequent in patients with CSU [29] and especially in females [30]. However, IgE antibodies to TPO have also been detected [31, 32] suggesting a possible mode of action for the benefit of

**Table 2 Frequency of various autoimmune diseases in CSU**

| Autoimmune condition   | Level of risk  |
|--|--|
| Hashimoto's thyroiditis  | Overt hypothyroidism about 5% although anti-TPO abs can be found between 10 and 20% This figure varies between studies |
| Pernicious anaemia   | 5%   |
| Grave's disease  | 5%   |
| Vitiligo   | 5%   |
| Insulin dependent diabetes   | > 1%   |
| Coeliac disease  | > 1%   |
| Rheumatoid arthritis   | > 1%   |
| Polyglandular syndrome with autoimmune thyroid disease, pernicious anaemia and or vitiligo | > 1%   |
| Systemic connective tissue disorders e.g. lupus, MCTD etc.                                 | Same as background population prevalence   |

anti-IgE therapy in CSU. Interesting recent work also suggests that a high proportion of the total IgE in those with CSU may be autoreactive and have increased lipophilicity [33]. Regardless, IgG antibodies directly binding to the FcεRI and in consequence capable of activating mast cells have been and found in almost a quarter of patients with CSU with only 3.2% in healthy controls [34]. This has kindled interest in mast cell activating IgE and IgG autoantibodies directed to thyroid and nuclear antigens. Interestingly, passive transfer of IgE anti-TPO antibodies could elicit positive skin prick test response in control subjects and basophils from patients with CSU and anti-TPO antibodies could be activated by incubation with TPO [35]. At a more basic level, auto-antibodies in general may encourage the secretion of Type I interferons by plasmacytoid dendritic cells (pDC) [36] and stimulate recruitment of basophils to lymph nodes and directly activate adaptive immune responses through B and T cells [37]. In an interesting recent report IgE antibodies to IL24 functionally capable of activating mast cells and correlating with disease activity have been reported by Schmetzer et al. [38]. The authors also noted IgE auto-antibodies to over 200 self-proteins from a total of over 9000 proteins screened. The avidity of these antibodies remains unclear and it is possible that they represent non-specifically auto-reactive antibodies generated as part of a polyclonal humoral response to a viral or other infection.

Clinically the increased prevalence of autoimmunity in CSU suggests impaired immune regulation and an imbalance in the ratio of the pro-inflammatory Th17 cells and T regulatory cells (Tregs). Tregs dysfunction, and especially T follicular regulatory cells [39], leading to the survival of autoreactive T and B cells and altered antigen presenting function by dendritic cells may underlie several systemic and organ specific autoimmune diseases [40, 41]. In this regard, it is noteworthy that impaired T regulatory (Treg) cell function has been found in CSU [42, 43] with alterations in other T cell subsets also being evident [44]. From a therapeutic perspective efforts to improve T reg function may therefore be helpful to reduce the severity and duration of CSU. At present this has been utilised predominantly in graft versus host disease after hematopoietic stem cell transplantation [45].

### Infections

While the precise cause of CSU is often unclear in an individual patient, viral infections and increased stress levels may be important factors in Western countries [46]. Globally, however, parasitic infections may be of greater importance with an average comorbidity of around 10% [47]. In this group anisakiasis, toxocariasis,

ascariasis, strongyloidiasis and blastocystosis were the most frequent parasitic infections and treatment led to improvement in an average of one-third of patients across several studies [47]. In this regard, empirical anti-helminth therapy was suggested by Nahshoni et al. [48] for people with CSU returning from travel to 'developing countries'. Earlier work by Hameed et al. [49] suggested that the urticaria could be more properly linked with the amoeboid form of blastocystis hominis. Furthermore, 60% of these patients responded to a single course of metronidazole and 100% to two courses.

More recent work has shown an increased frequency of dysbiosis of the gastrointestinal tract in CSU. As such there was a significantly reduced frequency of *Akkermansia muciniphila*, *Clostridium leptum* and *Faecalibacterium prausnitzii* in the stools of CSU patients while that of Enterobacteriaceae was unchanged [50]. Intriguingly, the number of tryptase and CD117 positive mast cells per high power field were significantly higher in patients with CSU compared to controls and adjunctive treatment with mast cell stabilisers has been suggested [51].

In regards to the role of helicobacter infection the precise significance of this infection in precipitating and/or aggravating CSU has oscillated over the years. More recent work suggests that asymptomatic infection is more frequent in CSU patients than in healthy controls and in helicobacter infection positive patients the severity and extent of the urticaria may be more severe [52].

In terms of CSU and infections outside of the GI tract, there are numerous anecdotal reports or small case series that have purported to show a link with viral, bacterial or fungal infections. Thus, Dreyfus [53] noted serological evidence of human herpes virus 6 infection, sometimes in association with Epstein Barr virus reactivation, to be more frequent in patients with CSU. In their systematic review, Imbalzano et al. [54] considered herpes viruses to be possible aetiologic factors in children and hepatitis viruses were more frequently associated with CSU in adults. The precise role of so-called 'superallergens' that can non-specifically stimulate basophils and mast cells and which are produced in viral infections such as hepatitis C and HIV is unclear [55].

In the case of bacterial infections, Calado et al. [56] found streptococcal tonsillar infection to relate to CSU with improvement after antibiotic therapy and more permanent resolution after tonsillectomy. Godse and Zawar [57] found a link with tinea pedis in four patients with significant improvement after anti-fungal therapy. However, Cribier and Noacco [58] did not support a definite link between focal infections such as sinusitis and dental infections and CSU. They also mentioned the importance of curative antibiotic therapy in eliminating

CSU as clearly supporting an aetiological link and this was frequently absent in the case of focal infections.

The mechanism by which infection contributes to the onset, perpetuation or worsening of CSU is unclear. It is possible that different components of the immune response to infection may be responsible in varying combinations to these different stages in CSU. As such Kay et al. [59] reported increased cellular expression of the Th2 cytokines IL4 and IL5 as well as IL33, IL25 and thymic stromal lymphopoietin in the lesional but not non-lesional skin of patients with CSU. Notably, the IL25 and IL33 was expressed by multiple cells involved in the innate immune system. In the case of helicobacter infection, a 23 to 35 kDa protein obtained from helicobacter preparations was found to induce the release of histamine, TNF- $\alpha$ , IL-3, IFN- $\gamma$ , and leukotriene B4 by the LAD2 mast cell line in a dose or time-dependent manner [60]. Additionally, mast cells can be activated by inflammatory cytokines such as IL6 [61] and raised levels of IL6, IL1 $\beta$  and TNF $\alpha$  have been reported in patients with infection and in CSU [62]. It is therefore not inconceivable that infections associated with inflammation may be associated with urticaria. Indeed, some patients with CSU have been improved by the discovery and treatment of occult infection [63]. Overall, however, it is likely that infection acts as a facilitating factor for the initiation and perpetuation of CSU and additional cofactors such as stress may be required for the CSU phenotype to be expressed. This would explain why few patients with severe infections such as a pneumonia, pyelonephritis, abscess etc. develop urticaria.

### **Stress and altered mood**

Urticaria has been reported to be increased in frequency in patients with bipolar disorder [64] which is well known to be accompanied by high levels of stress. CSU is also associated with a significantly higher prevalence of depression, anxiety and poor quality of sleep [3, 65]. In the recent report by Tat [66], depression and anxiety assessed using the Hospital Anxiety and Depression scale was evident in almost half of the 50 CSU patients seen and with a significant positive correlation of both with the urticaria activity score. Regardless, the coexistence of mood disturbance with CSU can have major repercussions for work attendance and efficiency [3, 14]. In children, high rates of various sorts of anxiety as well as social phobia and depression have also been reported [67]. Interestingly, 'state anger' measured using the State trait anger expression inventory correlated significantly with levels of pruritis [68]. High levels of anger were also reported by Altinöz et al. [69]. Overall, there is increasing

evidence that continued stress can perpetuate and aggravate CSU.

As mentioned previously, patients with CSU have increased levels of emotional distress with an underlying anxiety, depression and somatoform disorder [12]. Conversely, increased levels of stress may perhaps predispose individuals to CSU. As such Yang et al. [70] noted significantly more 'life events, higher subjective weighting of impacts from life events, more somatic symptoms, more severe insomnia, less family support and more negative coping tendencies' in 75 consecutively seen CSU patients than 133 control patients with tinea pedis. However, the mechanism by which stress predisposes to CSU is unclear. Interestingly, the basophils of patients with CSU appear to activate more readily with adrenocorticotrophic hormone and corticotrophin releasing factor and to have had a trend to raised cortisol levels compared to healthy controls [71]. Additionally, in mice, stress can lead to a disruption of T regulatory cell function with a shift towards a Th1/Th17 balance leading to exaggerated autoimmunity [72]. In children, stress has been associated with an increased tendency to autoreactive T and B cells and with the production of IgG auto-antibodies [73]. Increased activation of the NLRP-3 inflammasome has also been demonstrated in major depression and stress and this may provide the link between psychological factors and exacerbation of urticaria by changes in mood and especially emotional stress [74].

The link between the brain and mast cells within the skin via C fibre sensory nerves is likely involved in the worsening of skin diseases such as atopic dermatitis and CSU with stress [75]. The increased frequency of CSU in women is likely related to oestrogen and progesterone and the ability of these hormones to stimulate autoimmunity [5]. However, recent work also suggests the importance of pituitary adenylate cyclase activating polypeptide in stress circuits and stress responses and which is modulated by oestrogen [76]. In terms of the chemical link between nerves and mast cells, several neuropeptides, but particularly substance P are able to activate mast cells [77] leading to the release of histamine and related mediators that are involved in CSU. Interestingly neuropeptides such as vasoactive intestinal peptide,  $\alpha$ -melanocyte-stimulating hormone and calcitonin gene-related peptide (CGRP) are evident both within the central nervous system and released by cutaneous nerves [78, 79]. In this regards it is noteworthy that stress leading to the release of sensory nerve neuropeptides can alter the behaviour of Langerhans cells within the dermis and skew the cutaneous immune system towards specific T helper cell pathways [80]. CGRP, in particular, appears to encourage Th17 type



cells with the potential to increase inflammation by the recruitment of T cells and neutrophils [78, 81].

Recent work suggests that stress induced release of substance P and CGRP by sensory cutaneous nerves leads to itching and mast cell activation via several receptors. These include the Mas-related G protein-coupled receptors (Mrgpr) family as well as transient receptor potential ankyrin 1 (TRPA1) and protease activated receptor 2 (Par2) [78]. The subsequent release of cytokines such as IFN- $\gamma$ , IL-4, TNF- $\alpha$ , and IL-10 then encourages immune activation and the aggravation of cutaneous inflammation. It is therefore possible that the itch scratch cycle can prolong the cutaneous inflammation that perpetuates CSU and which is also seen in atopic dermatitis.

#### **Chronic inflammation, oxidative stress and metabolic syndrome**

Many patients with CSU are observed to have mildly raised levels of C-reactive protein. Determining the cause of this abnormality is frequently unrewarding. However, a state of immune readiness and inflammation has been suggested to be present in the peripheral blood of CSU patients by Santos et al. [82]. They reported significantly higher serum levels of several chemokines (CXCL8, CXCL9, CXCL10 and CCL2) in patients with CSU compared to healthy controls and this was irrespective of whether they were ASST positive. Furthermore, the basal secretion of CCL2 by peripheral blood mononuclear cells or induced by *Staphylococcus aureus* enterotoxin A was higher in those with CSU as indeed was CXCL8 and CCL5 secretion after phytohaemagglutinin stimulation.

In terms of oxidant stress, this has been found to be increased in children with CSU in whom total antioxidant activity was also reduced [83]. As such it is interesting that patients with CSU had lower levels of basal cortisol [84] and dehydroepiandrosterone-S (DHEA-S) [85]. Both are reduced in chronic stress and DHEA-S is partly regulated by the nervous system and is known to regulate the immune system. Furthermore, patients with CSU have an increased overall oxidative burden with reduced levels of erythrocyte copper-zinc superoxide dismutase (Cu-ZnSOD) levels [86]. This contrasts the situation in acute urticaria in which increased levels of oxidative stress indicated by raised levels of malonaldehyde and nitrous oxide were associated with increased Cu-ZnSOD and decreased levels of glutathione peroxidase [87].

Chronic low grade inflammation associated with high stress scores, raised C-reactive protein and interleukin 18 [84] may explain the increased frequency of metabolic syndrome in CSU [88, 89]. Hypertension was noted in 18.1% of the 1539 CSU patients that were analysed as

part of the German contribution to the AWARE study [90]. The mechanism by which hypertension may prolong CSU is, however, unclear [91] although it should be borne in mind that ACE inhibitors used in hypertension can aggravate and prolong CSU.

#### **Vitamin D3**

Vitamin D3 (cholecalciferol) has a powerful ability to increase T regulatory cell function and reduce Th1 and Th17 type immunity [92]. These immune changes can help ameliorate autoimmunity. In this regard, it is interesting that reduced levels of serum vitamin D3 have been found in several of the systemic autoimmune diseases as well as in asthma and inflammatory bowel disease. In CSU, reduced vitamin D levels are found more frequently than in healthy controls [93] and replacement therapy has been found to reduce the severity and duration of the urticarial wheals [94, 95].

#### **Coagulation pathways**

The involvement of the coagulation system in CSU is suggested by the clinical improvement in urticaria when patients are commenced on anticoagulation for other apparently unconnected reasons. Indeed, the present authors have seen this in 5 patients over the years. This is supported by the elevated d-dimer noted by Triwongwanat et al. [96] in 58 out of 120 patients with CSU and with a correlation between d-dimer levels and severity of urticaria. Prior to this Sakurai et al. [97] observed increased thrombin generation by the peripheral blood cells of patients with CSU compared to healthy controls. In this respect, it is interesting that thrombin injected into the ear skin of mice produced a dose dependent degranulation of mast cells and the mast cells expressed thrombin receptors PARs 1, 3 and 4 [98]. Elevation of other coagulation variables has also been observed by other authors and treatment with anti-coagulant drugs as adjunctive therapy suggested [99]. More recently Yanase et al. [100] have suggested the involvement of the extrinsic coagulation pathway in CSU and highlighted the role of tissue factor expression of endothelial cells as being important. Notwithstanding, the precise mechanism by which coagulation contributes to urticaria is unclear although the interaction between inflammatory factors and coagulation proteins is interesting [101].

#### **Altered gut permeability**

Patients with coeliac disease have been shown to have an increased frequency [28] and susceptibility to both acute and chronic urticaria with odds ratios of 1.31; 95% CI 1.12–1.52 and 1.54; 95% CI 1.08–2.18, respectively [102]. The mechanism here is unclear but as coeliac

disease is increased in those with IgA deficiency and the latter is associated with autoimmunity this may represent one possible mechanism. Additionally, coeliac disease is associated increased permeability of the upper gastrointestinal tract which may allow the greater absorption of pseudoallergens. Furthermore, vitamin D deficiency is more frequent in coeliac disease which may in turn contribute to impaired T regulatory cell function and raised tendency to autoimmunity.

### Linking the different factors that facilitate the onset of CSU

The ability of pseudoallergens, infections and stress to initiate and/or aggravate CSU suggests that a common pathway may be involved. However, in some patients with CSU type 1 and 2a immune hypersensitivity with specific IgE and autoreactive IgG antibodies may be directly involved in activating mast cells. In this case the condition continues until the respective IgE and autoreactive B cells are lost or the antigenic stimulus is eliminated. However, an increased frequency of autoimmunity has been linked to stress [5, 73, 103–106] and several viral infections, but especially Epstein Barr, can encourage autoimmunity [107, 108]. The mechanisms here involve a combination of impaired T regulatory activity and specific viral proto-oncogenes that give a survival stimulus to low avidity auto-reactive B cells. These would normally suffer spontaneous demise or be actively eliminated. Consequently, certain infections and stress may be linked to an increase susceptibility to CSU by perturbation of the immune system.


In the case of factors that facilitate the development of CSU, the role of the Mas related G protein coupled X2 receptor (MRGPRX2) found on mast cells may be relevant. Thus, increased expression has been found on the mast cells of patients with CSU compared to healthy controls [109]. Importantly, MRGPX2, previously known as MrgX2, can be stimulated by antimicrobial host defense peptides such as  $\beta$ -defensins and the cathelicidin LL-37 [110], neuropeptides such as substance P [109] and vasoactive intestinal peptide, major basic protein, eosinophil peroxidase, and several peptidergic drugs [10, 11]. Importantly, these multiple means of mast cell activation open the possibility that simultaneous subthreshold stimulation by several factors may cumulatively leading to mast cell degranulation and CSU. Thus, infection associated with host immune cell secreted defence peptides occurring during a period of stress and with an increased ingestion of foods with preservatives and colourings may together lead to urticaria whereas these factors alone may be insufficient. Moreover, the unpredictable

continuation of the urticaria associated with raised stress levels may then perpetuate the CSU even when the original infection has been eliminated and there has been an improvement in the diet.

Varying degrees and patterns of inflammation are evident in CSU. In some there is a typical IgE mediated response with only low level lymphocytic and eosinophilic infiltration. In other cases, there is a greater involvement of neutrophils and mononuclear cells perhaps suggesting raised Th17 function. The pro-inflammatory cytokines mediating the latter type of immune response if unchecked for a prolonged period would likely aggravate and perpetuate CSU by encouraging inflammatory cell infiltration. However, the situation is rendered more complex by the ability of TNF- $\alpha$  to increase Tregs [45] and the fact there are several types of Tregs with slightly differing functions and ability to reduce autoimmunity [111].

### Therapeutic relevance of autoimmunity, pseudoallergens, stress, low vitamin D, infection and increased tendency to coagulation in CSU

The interaction of the more important factors that impact on CSU are shown in Fig. 2. Here it can be seen that many of the factors are interlinked and can directly or indirectly exacerbate CSU. Attention to each of these areas should form the basis of the holistic treatment of all patients with CSU. Regardless, most patients with CSU controlled by conventional dose second generation anti-histamine therapy do not require investigation according to the European and World Allergy Organisation guidelines on urticaria [112]. However, those unresponsive to high dose antihistamine therapy used up to quadruple levels may benefit from investigation for underlying autoimmunity, hypovitaminosis D, gastrointestinal dysbiosis and possibly helicobacter infection [113] depending on their clinical evaluation. Appropriate therapy should then be offered including vitamin D3, probiotics, anti-microbials



and levothyroxine. The latter should certainly be offered if hypothyroidism is discovered [114]. The use of colouring and preservative free diets remains controversial but worth considering on a temporary basis in those patients who regularly consume pre-packaged food.

It has previously been shown that desloratadine can reduce oxidative damage to erythrocytes by increasing the activity of superoxide dismutase [115]. Thus, at least some anti-histamine therapies may work by both reducing the activity of histamine released by activated mast cells but also increasing anti-oxidative pathways that reduce inflammation. However, it is unclear whether oral anti-oxidant therapy provides any benefit to CSU patients on maximal anti-histamine therapy. Regardless, it should undoubtedly be considered in those with obvious poor diet and agents such as vitamin E and N-acetyl cysteine with their very low side effect profiles are ideal.

In rare reports, anti-coagulants have also been reported to be helpful in CSU patients with severe disease [116]. Although some have suggested that full carefully monitored anti-coagulation is required for efficacy [117] this is not always so. Indeed, some patients simply require low dose anti-coagulation that does not necessarily increase the prothrombin time or international normalised ratio. Indeed, low dose warfarin therapy was used with significant anecdotal benefit in the late 1980s.

As stress is a common precipitating or perpetuating factor in virtually all patients with CSU [118], efforts to uncover any obvious sources is important [12]. As such stress reduction therapy using a variety of approaches [119] may be helpful in improving CSU and should be considered as an important and early intervention to limit morbidity and improve overall quality of life. Interestingly, there is one report on the positive value of hypnotherapy in CSU although the benefit was most evident in those individuals who were considered hypnotizable [120].

At present anti-IgE therapy is recommended as third line treatment of severe CSU unresponsive to combinations of high dose anti-histamines [112]. The efficacy of additional leukotriene receptor antagonist therapy is unclear. Anti-IgE therapy appears at present to have very few short and long term side effects and is often better tolerated ciclosporin. There is also some evidence that it can normalise abnormal gene transcript signatures in lesional skin [121]. For the future, efforts to increase Tregs function and reduce Th17 activity would appear appropriate. This would be especially so in patients with severe CSU unresponsive even to anti-IgE therapy and perhaps especially in those with a positive autologous skin tests.

## Conclusion

The threshold for developing CSU is reduced by several common conditions while others frequently modify the condition or prolong its duration. These conditions are associated with impaired immune regulation and/or an underlying pro-inflammatory state and contribute to mast cell irritability and an increasing tendency to autoimmunity. The latter is often directed towards IgG and IgE cell surface receptors. Persistent stress and mild underlying infection is frequently evident in CSU and can activate mast cells via several neuropeptides and anti-microbial host defence proteins acting through the MRGPRX2. All factors known to affect urticaria should be addressed in the investigation and management of this condition. This may lessen the severity and duration of the CSU with a lowered need to use second and third line therapies.

## Abbreviations

CGRP: calcitonin gene-related peptide; CSU: chronic spontaneous urticaria; DHEA-S: dehydroepiandrosterone-S; IL: interleukin; IFN: interferon; MRGPRX2: Mas related G protein coupled X2 receptor; Th: T helper cells; TNF: tumour necrosis factor; Tregs: T regulatory cells.

## Acknowledgements

Professor Marcus Maurer for some of his thoughts on CSU and its aetiology.

## Authors' contributions

Both authors contributed equally to the writing of this manuscript. Both authors read and approved the final manuscript.

## Funding

No funding was required or used in the construction of this manuscript.

## Availability of data and materials

Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.

## Ethics approval and consent to participate

Not applicable.

## Consent for publication

Not applicable.

## Competing interests

The authors declare that they have no competing interests.

## Author details

<sup>1</sup> St Barts, Queen Mary's University, London, UK. <sup>2</sup> St Helier Hospital, Carshalton, Surrey SM5 1AA, UK.

Received: 24 May 2019 Accepted: 4 September 2019

Published online: 11 September 2019

## References

- Eun SJ, Lee JY, Kim DY, Yoon HS. Natural course of new-onset urticaria: results of a 10-year follow-up, nationwide, population-based study. *Allergol Int.* 2019;68(1):52–8.
- Kay AB, Ying S, Ardelean E, Mlynek A, Kita H, Clark P, et al. Elevations in vascular markers and eosinophils in chronic spontaneous urticarial wheals with low-level persistence in uninvolved skin. *Br J Dermatol.* 2014;171(3):505–11.



3. Balp MM, Vietri J, Tian H, Isherwood G. The impact of chronic urticaria from the patient's perspective: a survey in five European countries. *Patient*. 2015;8(6):551–8.
4. Lapi F, Cassano N, Pegoraro V, Cataldo N, Heiman F, Cricelli I, et al. Epidemiology of chronic spontaneous urticaria: results from a nationwide, population-based study in Italy. *Br J Dermatol*. 2016;174(5):996–1004.
5. Assad S, Khan HH, Ghazanfar H, Khan ZH, Mansoor S, Rahman MA, et al. Role of sex hormone levels and psychological stress in the pathogenesis of autoimmune diseases. *Cureus*. 2017;9(6):e1315.
6. Dionigi PC, Menezes MC, Forte WC. A prospective ten-year follow-up of patients with chronic urticaria. *Allergol Immunopathol*. 2016;44(4):286–91.
7. Sanchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F, Gonzalez-Aveledo L. Justification for IgE as a therapeutic target in chronic spontaneous urticaria. *Eur Ann Allergy Clin Immunol*. 2017;49(4):148–53.
8. Augey F, Gunera-Saad N, Bensaid B, Nosbaum A, Berard F, Nicolas JF. Chronic spontaneous urticaria is not an allergic disease. *Eur J Dermatol*. 2011;21(3):349–53.
9. Rosman Y, Hershko AY, Meir-Shafir K, Kedem R, Lachover-Roth I, Mekori YA, et al. Characterization of chronic urticaria and associated conditions in a large population of adolescents. *J Am Acad Dermatol*. 2019;81:129–35.
10. Subramanian H, Gupta K, Ali H. Roles of Mas-related G protein-coupled receptor X2 on mast cell-mediated host defense, pseudoallergic drug reactions, and chronic inflammatory diseases. *J Allergy Clin Immunol*. 2016;138(3):700–10.
11. Olivera A, Beaven MA, Metcalfe DD. Mast cells signal their importance in health and disease. *J Allergy Clin Immunol*. 2018;142(2):381–93.
12. Staubach P, Dechene M, Metz M, Magerl M, Siebenhaar F, Weller K, et al. High prevalence of mental disorders and emotional distress in patients with chronic spontaneous urticaria. *Acta Derm Venereol*. 2011;91(5):557–61.
13. Vestergaard C, Deleuran M. Chronic spontaneous urticaria: latest developments in aetiology, diagnosis and therapy. *Ther Adv Chronic Dis*. 2015;6(6):304–13.
14. Vietri J, Turner SJ, Tian H, Isherwood G, Balp MM, Gabriel S. Effect of chronic urticaria on US patients: analysis of the National Health and Wellness Survey. *Ann Allergy Asthma Immunol*. 2015;115(4):306–11.
15. Wöhrl S. NSAID hypersensitivity—recommendations for diagnostic work up and patient management. *Allergo J Int*. 2018;27(4):114–21.
16. Thong BYH. Nonsteroidal anti-inflammatory drug hypersensitivity in the Asia-Pacific. *Asia Pac Allergy*. 2018;8(4):e38.
17. Perkins JR, Acosta-Herrera M, Plaza-Seron MC, Jurado-Escobar R, Dona I, Garcia-Martin E, et al. Polymorphisms in CEP68 gene associated with risk of immediate selective reactions to non-steroidal anti-inflammatory drugs. *Pharmacogenomics J*. 2019;19(2):191–9.
18. Akoglu G, Atakan N, Cakir B, Kalayci O, Hayran M. Effects of low pseudoallergen diet on urticarial activity and leukotriene levels in chronic urticaria. *Arch Dermatol Res*. 2012;304(4):257–62.
19. Magerl M, Pisarevskaja D, Scheufele R, Zuberbier T, Maurer M. Effects of a pseudoallergen-free diet on chronic spontaneous urticaria: a prospective trial. *Allergy*. 2010;65(1):78–83.
20. Siebenhaar F, Melde A, Magerl M, Zuberbier T, Church MK, Maurer M. Histamine intolerance in patients with chronic spontaneous urticaria. *J Eur Acad Dermatol Venereol*. 2016;30(10):1774–7.
21. Cornillier H, Giraudeau B, Samimi M, Munck S, Hacard F, Jonville-Bera AP, et al. Effect of diet in chronic spontaneous urticaria: a systematic review. *Acta Derm Venereol*. 2019;99(2):127–32.
22. Henz BM, Zuberbier T. Most chronic urticaria is food-dependent, and not idiopathic. *Exp Dermatol*. 1998;7(4):139–42.
23. Rajan JP, Simon RA, Bosso JV. Prevalence of sensitivity to food and drug additives in patients with chronic idiopathic urticaria. *J Allergy Clin Immunol Pract*. 2014;2(2):168–71.
24. Buhner S, Reese I, Kuehl F, Lochs H, Zuberbier T. Pseudoallergic reactions in chronic urticaria are associated with altered gastroduodenal permeability. *Allergy*. 2004;59(10):1118–23.
25. Kumaran MS, Mangal S, Narang T, Parsad D. Autologous serum and plasma skin tests in chronic spontaneous urticaria: a reappraisal. *Indian Dermatol Online J*. 2017;8(2):94–9.
26. Magen E, Zueva E, Mishal J, Schlesinger M. The clinical and laboratory characteristics of acute spontaneous urticaria and its progression to chronic spontaneous urticaria. *Allergy Asthma Proc*. 2016;37(5):394–9.
27. Boonpiyathad T, Sangasapaviliya A. Autologous serum and plasma skin test to predict 2-year outcome in chronic spontaneous urticaria. *Asia Pac Allergy*. 2016;6(4):226–35.
28. Confino-Cohen R, Chodick G, Shalev V, Leshno M, Kimhi O, Goldberg A. Chronic urticaria and autoimmunity: associations found in a large population study. *J Allergy Clin Immunol*. 2012;129(5):1307–13.
29. Kolkhir P, Borzova E, Grattan C, Asero R, Pogorelov D, Maurer M. Autoimmune comorbidity in chronic spontaneous urticaria: a systematic review. *Autoimmun Rev*. 2017;16(12):1196–208.
30. Najib U, Bajwa ZH, Ostro MG, Sheikh J. A retrospective review of clinical presentation, thyroid autoimmunity, laboratory characteristics, and therapies used in patients with chronic idiopathic urticaria. *Ann Allergy Asthma Immunol*. 2009;103(6):496–501.
31. Kolkhir P, Metz M, Altrichter S, Maurer M. Comorbidity of chronic spontaneous urticaria and autoimmune thyroid diseases: a systematic review. *Allergy*. 2017;72(10):1440–60.
32. Altrichter S, Peter HJ, Pisarevskaja D, Metz M, Martus P, Maurer M. IgE mediated autoallergy against thyroid peroxidase—a novel pathomechanism of chronic spontaneous urticaria? *PLoS ONE*. 2011;6(4):e14794.
33. Lakin E, Church MK, Maurer M, Schmetzer O. On the lipophilic nature of autoreactive IgE in chronic spontaneous urticaria. *Theranostics*. 2019;9(3):829–36.
34. Ulambayar B, Chen YH, Ban GY, Lee JH, Jung CG, Yang EM, et al. Detection of circulating IgG autoantibody to Fcεpsilon1alpha in sera from chronic spontaneous urticaria patients. *J Microbiol Immunol Infect*. 2017. <https://doi.org/10.1016/j.jmii.2017.10.003>.
35. Sanchez J, Sanchez A, Cardona R. Causal relationship between anti-TPO IgE and chronic urticaria by in vitro and in vivo tests. *Allergy Asthma Immunol Res*. 2019;11(1):29–42.
36. Henault J, Riggs JM, Karnell JL, Liarski VM, Li J, Shirinian L, et al. Self-reactive IgE exacerbates interferon responses associated with autoimmunity. *Nat Immunol*. 2016;17(2):196–203.
37. Ettinger R, Karnell JL, Henault J, Panda SK, Riggs JM, Kolbeck R, et al. Pathogenic mechanisms of IgE-mediated inflammation in self-destructive autoimmune responses. *Autoimmunity*. 2017;50(1):25–36.
38. Schmetzer O, Lakin E, Topal FA, Preusse P, Freier D, Church MK, et al. IL-24 is a common and specific autoantigen of IgE in patients with chronic spontaneous urticaria. *J Allergy Clin Immunol*. 2018;142(3):876–82.
39. Fu W, Liu X, Lin X, Feng H, Sun L, Li S, et al. Deficiency in T follicular regulatory cells promotes autoimmunity. *J Exp Med*. 2018;215(3):815–25.
40. Qiao YC, Pan YH, Ling W, Tian F, Chen YL, Zhang XX, et al. The Yin and Yang of regulatory T cell and therapy progress in autoimmune disease. *Autoimmun Rev*. 2017;16(10):1058–70.
41. Yu H, Paiva R, Flavell RA. Harnessing the power of regulatory T-cells to control autoimmune diabetes: overview and perspective. *Immunology*. 2018;153(2):161–70.
42. Arshi S, Babaie D, Nabavi M, Tebianian M, Ghalehbaghi B, Jalali F, et al. Circulating level of CD4+ CD25+ FOXP3+ T cells in patients with chronic urticaria. *Int J Dermatol*. 2014;53(12):e561–6.
43. Chen WC, Chiang BL, Liu HE, Leu SJ, Lee YL. Defective functions of circulating CD4+ CD25+ and CD4+ CD25- T cells in patients with chronic ordinary urticaria. *J Dermatol Sci*. 2008;51(2):121–30.
44. Moy AP, Murali M, Nazarian RM. Identification of a Th2- and Th17-skewed immune phenotype in chronic urticaria with Th22 reduction dependent on autoimmunity and thyroid disease markers. *J Cutan Pathol*. 2016;43(4):372–8.
45. Mancusi A, Piccinelli S, Velardi A, Pierini A. The effect of TNF-α on regulatory T cell function in graft-versus-host disease. *Front Immunol*. 2018;9:356.
46. Caffarelli C, Cuomo B, Cardinale F, Barberi S, Dascola CP, Agostini F, et al. Aetiological factors associated with chronic urticaria in children: a systematic review. *Acta Derm Venereol*. 2013;93(3):268–72.
47. Kolkhir P, Balakirski G, Merk HF, Olisova O, Maurer M. Chronic spontaneous urticaria and internal parasites—a systematic review. *Allergy*. 2016;71(3):308–22.

48. Nahshoni A, Baum S, Barzilai A, Schwartz E. Chronic urticaria in returning travellers: the role of anthelmintic treatment. *Dermatology*. 2016;232(4):468–71.
49. Hameed DM, Hassanin OM, Zuel-Fakkar NM. Association of *Blastocystis hominis* genetic subtypes with urticaria. *Parasitol Res*. 2011;108(3):553–60.
50. Nabizadeh E, Jazani NH, Bagheri M, Shahabi S. Association of altered gut microbiota composition with chronic urticaria. *Ann Allergy Asthma Immunol*. 2017;119(1):48–53.
51. Minnei F, Wetzels C, De Hertogh G, Van Eyken P, Ectors N, Ambu R, et al. Chronic urticaria is associated with mast cell infiltration in the gastroduodenal mucosa. *Virchows Arch*. 2006;448(3):262–8.
52. Kohli S, Mahajan VK, Rana BS, Mehta KS, Raina RK, Chauhan PS, et al. Clinicoepidemiologic features of chronic urticaria in patients with versus without subclinical *helicobacter pylori* infection: a cross-sectional study of 150 patients. *Int Arch Allergy Immunol*. 2018;175(1–2):114–20.
53. Dreyfus DH. Serological evidence that activation of ubiquitous human herpesvirus-6 (HHV-6) plays a role in chronic idiopathic/spontaneous urticaria (CIU). *Clin Exp Immunol*. 2016;183(2):230–8.
54. Imbalzano E, Casciaro M, Quartuccio S, Minciullo PL, Cascio A, Calapai G, et al. Association between urticaria and virus infections: a systematic review. *Allergy Asthma Proc*. 2016;37(1):18–22.
55. Marone G, Rossi FW, Detoraki A, Granata F, Genovese A, Spadaro G. Role of superallergens in allergic disorders. *Chem Immunol Allergy*. 2007;93:195–213.
56. Calado G, Loureiro G, Machado D, Tavares B, Ribeiro C, Pereira C, et al. Streptococcal tonsillitis as a cause of urticaria: tonsillitis and urticaria. *Allergol Immunopathol (Madr)*. 2012;40(6):341–5.
57. Godse KV, Zawar V. Chronic urticaria associated with tinea infection and success with antifungal therapy—a report of four cases. *Int J Infect Dis*. 2010;14(Suppl 3):e364–5.
58. Cribier B, Noacco G. Chronic urticaria and infectious diseases. *Ann Dermatol Venereol*. 2003;130(Spec No 1):1s43–52.
59. Kay AB, Clark P, Maurer M, Ying S. Elevations in T-helper-2-initiating cytokines (interleukin-33, interleukin-25 and thymic stromal lymphopoietin) in lesional skin from chronic spontaneous ('idiopathic') urticaria. *Br J Dermatol*. 2015;172(5):1294–302.
60. Tan RJ, Sun HQ, Zhang W, Yuan HM, Li B, Yan HT, et al. A 21–35 kDa mixed protein component from *helicobacter pylori* activates mast cells effectively in chronic spontaneous urticaria. *Helicobacter*. 2016;21(6):565–74.
61. Desai A, Jung MY, Olivera A, Gilfillan AM, Prussin C, Kirshenbaum AS, et al. IL-6 promotes an increase in human mast cell numbers and reactivity through suppression of suppressor of cytokine signaling 3. *J Allergy Clin Immunol*. 2016;137(6):1863–71.
62. Hong GU, Ro JY, Bae Y, Kwon IH, Park GH, Choi YH, et al. Association of TG2 from mast cells and chronic spontaneous urticaria pathogenesis. *Ann Allergy Asthma Immunol*. 2016;117(3):290–7.
63. Colgecen E, Ozyurt K, Gul AI, Utas S. Evaluation of etiological factors in patients with chronic urticaria. *Acta Dermatovenereol Croat*. 2015;23(1):36–42.
64. Perugi G, Quaranta G, Belletti S, Casalini F, Mosti N, Toni C, et al. General medical conditions in 347 bipolar disorder patients: clinical correlates of metabolic and autoimmune-allergic diseases. *J Affect Disord*. 2015;170:95–103.
65. Chung MC, Symons C, Gilliam J, Kaminski ER. Stress, psychiatric co-morbidity and coping in patients with chronic idiopathic urticaria. *Psychol Health*. 2010;25(4):477–90.
66. Tat TS. Higher levels of depression and anxiety in patients with chronic urticaria. *Med Sci Monit*. 2019;25:115–20.
67. Herguner S, Kilic G, Karakoc S, Tamay Z, Tuzun U, Guler N. Levels of depression, anxiety and behavioural problems and frequency of psychiatric disorders in children with chronic idiopathic urticaria. *Br J Dermatol*. 2011;164(6):1342–7.
68. Conrad R, Geiser F, Haidl G, Hutmacher M, Liedtke R, Wermter F. Relationship between anger and pruritus perception in patients with chronic idiopathic urticaria and psoriasis. *J Eur Acad Dermatol Venereol*. 2008;22(9):1062–9.
69. Altinoz AE, Taskintuna N, Altinoz ST, Ceran S. A cohort study of the relationship between anger and chronic spontaneous urticaria. *Adv Ther*. 2014;31(9):1000–7.
70. Yang HY, Sun CC, Wu YC, Wang JD. Stress, insomnia, and chronic idiopathic urticaria—a case-control study. *J Formos Med Assoc*. 2005;104(4):254–63.
71. Dyke SM, Carey BS, Kaminski ER. Effect of stress on basophil function in chronic idiopathic urticaria. *Clin Exp Allergy*. 2008;38(1):86–92.
72. Harpaz I, Abutbul S, Nemirovsky A, Gal R, Cohen H, Monsonego A. Chronic exposure to stress predisposes to higher autoimmune susceptibility in C57BL/6 mice: glucocorticoids as a double-edged sword. *Eur J Immunol*. 2013;43(3):758–69.
73. Faresjo M. The link between psychological stress and autoimmune response in children. *Crit Rev Immunol*. 2015;35(2):117–34.
74. Kaufmann FN, Costa AP, Ghisleni G, Diaz AP, Rodrigues ALS, Peluffo H, et al. NLRP3 inflammasome-driven pathways in depression: clinical and preclinical findings. *Brain Behav Immun*. 2017;64:367–83.
75. Forsythe P, Bienenstock J. The mast cell-nerve functional unit: a key component of physiologic and pathophysiological responses. *Chem Immunol Allergy*. 2012;98:196–221.
76. King SB, Toufexis DJ, Hammack SE. Pituitary adenylate cyclase activating polypeptide (PACAP), stress, and sex hormones. *Stress*. 2017;20(5):465–75.
77. Kumagai M, Nagano M, Suzuki H, Kawana S. Effects of stress memory by fear conditioning on nerve-mast cell circuit in skin. *J Dermatol*. 2011;38(6):553–61.
78. Choi JE, Di Nardo A. Skin neurogenic inflammation. *Semin Immunopathol*. 2018;40(3):249–59.
79. Lotti T, D'Erme AM, Hercogova J. The role of neuropeptides in the control of regional immunity. *Clin Dermatol*. 2014;32(5):633–45.
80. Madva EN, Granstein RD. Nerve-derived transmitters including peptides influence cutaneous immunology. *Brain Behav Immun*. 2013;34:1–10.
81. Ding W, Stohl LL, Xu L, Zhou XK, Manni M, Wagner JA, et al. Calcitonin gene-related peptide-exposed endothelial cells bias antigen presentation to CD4+ T cells toward a Th17 response. *J Immunol*. 2016;196(5):2181–94.
82. Santos JC, de Brito CA, Futata EA, Azor MH, Orii NM, Maruta CW, et al. Up-regulation of chemokine C-C ligand 2 (CCL2) and C-X-C chemokine 8 (CXCL8) expression by monocytes in chronic idiopathic urticaria. *Clin Exp Immunol*. 2012;167(1):129–36.
83. Dilek F, Ozceker D, Ozkaya E, Guler N, Tamay Z, Kesgin S, et al. Oxidative stress in children with chronic spontaneous urticaria. *Oxid Med Cell Longev*. 2016;2016:3831071.
84. Varghese R, Rajappa M, Chandrashekar L, Kattimani S, Archana M, Munisamy M, et al. Association among stress, hypocortisolism, systemic inflammation, and disease severity in chronic urticaria. *Ann Allergy Asthma Immunol*. 2016;116(4):344–8.
85. Kasperska-Zajac A. Does dehydroepiandrosterone influence the expression of urticaria?—a mini review. *Inflammation*. 2011;34(5):362–6.
86. Sagdic A, Sener O, Bulucu F, Karadurmus N, Yamanel L, Tasci C, et al. Oxidative stress status in patients with chronic idiopathic urticaria. *Allergol Immunopathol*. 2011;39(3):150–3.
87. Kalkan G, Seckin HY, Duygu F, Akbas A, Ozyurt H, Sahin M. Oxidative stress status in patients with acute urticaria. *Cutan Ocul Toxicol*. 2014;33(2):109–14.
88. Shalom G, Magen E, Babaev M, Tiosano S, Vardy DA, Linder D, et al. Chronic urticaria and the metabolic syndrome: a cross-sectional community-based study of 11,261 patients. *J Eur Acad Dermatol Venereol*. 2018;32(2):276–81.
89. Vena GA, Cassano N. The link between chronic spontaneous urticaria and metabolic syndrome. *Eur Ann Allergy Clin Immunol*. 2017;49(5):208–12.
90. Maurer M, Staubach P, Raap U, Richter-Huhn G, Bauer A, Rueff F, et al. H1-antihistamine-refractory chronic spontaneous urticaria: it's worse than we thought—first results of the multicenter real-life AWARE study. *Clin Exp Allergy*. 2017;47(5):684–92.
91. Nebiolo F, Bergia R, Bommarito L, Bugiani M, Heffler E, Carosso A, et al. Effect of arterial hypertension on chronic urticaria duration. *Ann Allergy Asthma Immunol*. 2009;103(5):407–10.

92. Alhassan Mohammed H, Saboor-Yaraghi AA, Mirshafiey A, Vahedi H, Shiri-Shahsavari, Mousavi Nasl Khameneh A. Immunomodulatory and immunosuppressive roles of 1alpha,25(OH)2D3 in autoimmune diseases. *Scand J Immunol*. 2017;85(2):95–103.
93. Movahedi M, Tavakol M, Hirbod-Mobarakeh A, Gharagozlou M, Aghamohammadi A, Tavakol Z, et al. Vitamin D deficiency in chronic idiopathic urticaria. *Iran J Allergy Asthma Immunol*. 2015;14(2):222–7.
94. Oguz Topal I, Kocaturk E, Gungor S, Durmuscan M, Sucu V, Yildirmak S. Does replacement of vitamin D reduce the symptom scores and improve quality of life in patients with chronic urticaria? *J Dermatol Treat*. 2016;27(2):163–6.
95. Rasool R, Masoodi KZ, Shera IA, Yusuf Q, Bhat IA, Qasim I, et al. Chronic urticaria merits serum vitamin D evaluation and supplementation; a randomized case control study. *World Allergy Organ J*. 2015;8(1):1.
96. Triwongwanat D, Kulthanan K, Chularojanamontri L, Pinkaew S. Correlation between plasma D-dimer levels and the severity of patients with chronic urticaria. *Asia Pac Allergy*. 2013;3(2):100–5.
97. Sakurai Y, Morioka S, Takeda T, Takahagi S, Hide M, Shima M. Increased thrombin generation potential in patients with chronic spontaneous urticaria. *Allergol Int*. 2015;64(1):96–8.
98. Suender CA, Leist M, Abrink M, Valentini P, Geldmacher A, Steinhoff M, et al. Mast cells are critical for the limitation of thrombin-induced skin inflammation. *Exp Dermatol*. 2018;27(1):50–7.
99. Cugno M, Marzano AV, Asero R, Tedeschi A. Activation of blood coagulation in chronic urticaria: pathophysiological and clinical implications. *Intern Emerg Med*. 2010;5(2):97–101.
100. Yanase Y, Takahagi S, Hide M. Chronic spontaneous urticaria and the extrinsic coagulation system. *Allergol Int*. 2018;67(2):191–4.
101. Cugno M, Tedeschi A, Asero R, Meroni PL, Marzano AV. Skin autoimmunity and blood coagulation. *Autoimmunity*. 2010;43(2):189–94.
102. Ludvigsson JF, Lindelof B, Rashtak S, Rubio-Tapia A, Murray JA. Does urticaria risk increase in patients with celiac disease? A large population-based cohort study. *Eur J Dermatol*. 2013;23(5):681–7.
103. Carlsson E, Frostell A, Ludvigsson J, Faresjo M. Psychological stress in children may alter the immune response. *J Immunol*. 2014;192(5):2071–81.
104. Sepa A, Ludvigsson J. Psychological stress and the risk of diabetes-related autoimmunity: a review article. *Neuroimmunomodulation*. 2006;13(5–6):301–8.
105. Vita R, Lapa D, Trimarchi F, Vita G, Fallahi P, Antonelli A, et al. Certain HLA alleles are associated with stress-triggered Graves' disease and influence its course. *Endocrine*. 2017;55(1):93–100.
106. Welsh CJ, Steelman AJ, Mi W, Young CR, Dean DD, Storts R, et al. Effects of stress on the immune response to Theiler's virus—implications for virus-induced autoimmunity. *Neuroimmunomodulation*. 2010;17(3):169–72.
107. Morandi E, Jagessar SA, Hart A'tB, Gran B. EBV Infection empowers human B cells for autoimmunity: role of autophagy and relevance to multiple sclerosis. *J Immunol*. 2017;199(2):435–48.
108. Nagata K, Kumata K, Nakayama Y, Satoh Y, Sugihara H, Hara S, et al. Epstein–Barr Virus lytic reactivation activates b cells polyclonally and induces activation-induced cytidine deaminase expression: a mechanism underlying autoimmunity and its contribution to Graves' disease. *Viral Immunol*. 2017;30(3):240–9.
109. Fujisawa D, Kashiwakura J, Kita H, Kikukawa Y, Fujitani Y, Sasaki-Sakamoto T, et al. Expression of Mas-related gene X2 on mast cells is upregulated in the skin of patients with severe chronic urticaria. *J Allergy Clin Immunol*. 2014;134(3):622–33.
110. Ali H. Emerging roles for MAS-related G protein-coupled receptor-X2 in host defense peptide, opioid, and neuropeptide-mediated inflammatory reactions. *Adv Immunol*. 2017;136:123–62.
111. Alikhan MA, Huynh M, Kitching AR, Ooi JD. Regulatory T cells in renal disease. *Clin Transl Immunology*. 2018;7(1):e1004.
112. Zuberbier T, Aberer W, Asero R, Abdul Latif AH, Baker D, Ballmer-Weber B, et al. The EAACI/GA(2)LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. *Allergy*. 2018;73(7):1393–414.
113. Magen E, Delgado JS. *Helicobacter pylori* and skin autoimmune diseases. *World J Gastroenterol*. 2014;20(6):1510–6.
114. Kim DH, Sung NH, Lee AY. Effect of levothyroxine treatment on clinical symptoms in hypothyroid patients with chronic urticaria and thyroid autoimmunity. *Ann Dermatol*. 2016;28(2):199–204.
115. Sadowska-Woda I, Sychta B, Rachel M, Bieszczad-Bedrejczuk E. Protective effect of desloratadine against oxidative stress in human erythrocytes in vitro. *Environ Toxicol Pharmacol*. 2010;30(2):141–6.
116. Parslew R, Pryce D, Ashworth J, Friedmann PS. Warfarin treatment of chronic idiopathic urticaria and angio-oedema. *Clin Exp Allergy*. 2000;30(8):1161–5.
117. Samarasinghe V, Marsland AM. Class action of oral coumarins in the treatment of a patient with chronic spontaneous urticaria and delayed-pressure urticaria. *Clin Exp Dermatol*. 2012;37(7):741–3.
118. Kim S, Baek S, Shin B, Yoon SY, Park SY, Lee T, et al. Influence of initial treatment modality on long-term control of chronic idiopathic urticaria. *PLoS ONE*. 2013;8(7):e69345.
119. Lindsay K, Goulding J, Solomon M, Broom B. Treating chronic spontaneous urticaria using a brief 'whole person' treatment approach: a proof-of-concept study. *Clin Transl Allergy*. 2015;5:40.
120. Shertzer CL, Lookingbill DP. Effects of relaxation therapy and hypnotizability in chronic urticaria. *Arch Dermatol*. 1987;123(7):913–6.
121. Metz M, Torene R, Kaiser S, Beste MT, Staubach P, Bauer A, et al. Omalizumab normalizes the gene expression signature of lesional skin in patients with chronic spontaneous urticaria: a randomized, double-blind, placebo-controlled study. *Allergy*. 2019;74(1):141–51.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

